Cargando…
Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis
BACKGROUND: The optimal treatment for pulmonary metastases has not been determined, and the survival benefit of surgical resection in selected patients remains controversial. The purpose of this retrospective study was to explore whether surgery can prolong survival in patients with pulmonary metast...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080310/ https://www.ncbi.nlm.nih.gov/pubmed/37033339 http://dx.doi.org/10.21037/tcr-22-2286 |
_version_ | 1785020894253416448 |
---|---|
author | Gao, Kun Liu, Xianben Xing, Wenqun Sun, Haibo Liu, Shilei Li, Peng Chen, Peinan Zheng, Yan |
author_facet | Gao, Kun Liu, Xianben Xing, Wenqun Sun, Haibo Liu, Shilei Li, Peng Chen, Peinan Zheng, Yan |
author_sort | Gao, Kun |
collection | PubMed |
description | BACKGROUND: The optimal treatment for pulmonary metastases has not been determined, and the survival benefit of surgical resection in selected patients remains controversial. The purpose of this retrospective study was to explore whether surgery can prolong survival in patients with pulmonary metastases compared with chemotherapy, and to analyze the factors that may affect the long-term survival of patients with pulmonary metastases. METHODS: We retrospectively analyzed the medical records of patients with pulmonary metastases from June 2012 to June 2019. Propensity score matching (PSM) was used to balance factors that might affect survival between the two groups. The data were analyzed by Kaplan-Meier survival analysis and Cox proportional hazards models to compare the survival of the surgery group and the chemotherapy group. RESULTS: A total of 202 patients with pulmonary metastases were enrolled in the study, with 43 patients in the surgery group and 43 in the chemotherapy group after screening and PSM. After PSM, patients in the surgery group had better survival than those in the chemotherapy group, with 5-year overall survival (OS) rates of 75.1% and 48.0%, respectively (P=0.017). Univariate analysis of the two groups of patients found that the treatment method, the number of metastases, and the total diameter of metastases were prognostic factors, but multivariate analysis did not find independent prognostic factors. In the surgical group, univariate analysis found that disease-free interval (DFI), the number of metastases, surgical methods, resection scope and surgical route were prognostic factors, and multivariate analysis showed that only DFI was an independent prognostic factor. In the chemotherapy group, DFI and the response of metastases to chemotherapy were found to be prognostic factors in univariate analysis, but no independent prognostic factors were found in multivariate analysis. CONCLUSIONS: Surgery does not provide a significant survival advantage. For patients undergoing surgery, longer DFI predicts better survival. |
format | Online Article Text |
id | pubmed-10080310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-100803102023-04-08 Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis Gao, Kun Liu, Xianben Xing, Wenqun Sun, Haibo Liu, Shilei Li, Peng Chen, Peinan Zheng, Yan Transl Cancer Res Original Article BACKGROUND: The optimal treatment for pulmonary metastases has not been determined, and the survival benefit of surgical resection in selected patients remains controversial. The purpose of this retrospective study was to explore whether surgery can prolong survival in patients with pulmonary metastases compared with chemotherapy, and to analyze the factors that may affect the long-term survival of patients with pulmonary metastases. METHODS: We retrospectively analyzed the medical records of patients with pulmonary metastases from June 2012 to June 2019. Propensity score matching (PSM) was used to balance factors that might affect survival between the two groups. The data were analyzed by Kaplan-Meier survival analysis and Cox proportional hazards models to compare the survival of the surgery group and the chemotherapy group. RESULTS: A total of 202 patients with pulmonary metastases were enrolled in the study, with 43 patients in the surgery group and 43 in the chemotherapy group after screening and PSM. After PSM, patients in the surgery group had better survival than those in the chemotherapy group, with 5-year overall survival (OS) rates of 75.1% and 48.0%, respectively (P=0.017). Univariate analysis of the two groups of patients found that the treatment method, the number of metastases, and the total diameter of metastases were prognostic factors, but multivariate analysis did not find independent prognostic factors. In the surgical group, univariate analysis found that disease-free interval (DFI), the number of metastases, surgical methods, resection scope and surgical route were prognostic factors, and multivariate analysis showed that only DFI was an independent prognostic factor. In the chemotherapy group, DFI and the response of metastases to chemotherapy were found to be prognostic factors in univariate analysis, but no independent prognostic factors were found in multivariate analysis. CONCLUSIONS: Surgery does not provide a significant survival advantage. For patients undergoing surgery, longer DFI predicts better survival. AME Publishing Company 2023-02-13 2023-03-31 /pmc/articles/PMC10080310/ /pubmed/37033339 http://dx.doi.org/10.21037/tcr-22-2286 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Gao, Kun Liu, Xianben Xing, Wenqun Sun, Haibo Liu, Shilei Li, Peng Chen, Peinan Zheng, Yan Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis |
title | Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis |
title_full | Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis |
title_fullStr | Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis |
title_full_unstemmed | Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis |
title_short | Treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis |
title_sort | treatment outcomes of surgery and chemotherapy for pulmonary metastases from non-lung cancers: a propensity score-matched analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080310/ https://www.ncbi.nlm.nih.gov/pubmed/37033339 http://dx.doi.org/10.21037/tcr-22-2286 |
work_keys_str_mv | AT gaokun treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis AT liuxianben treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis AT xingwenqun treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis AT sunhaibo treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis AT liushilei treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis AT lipeng treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis AT chenpeinan treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis AT zhengyan treatmentoutcomesofsurgeryandchemotherapyforpulmonarymetastasesfromnonlungcancersapropensityscorematchedanalysis |